Apellis Pharmaceuticals, Inc.
Clinical trials sponsored by Apellis Pharmaceuticals, Inc., explained in plain language.
-
New hope for rare kidney diseases: early access drug available
Disease control APPROVED_FOR_MARKETINGThis program provides early access to pegcetacoplan for people aged 12 and older with C3 glomerulopathy or primary IC-MPGN, rare kidney diseases that cause protein in the urine and kidney damage. Participants must have active disease and limited response to other treatments. The …
Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 17, 2026 11:50 UTC
-
New eye drug syfovre under Real-World safety watch for blinding disease
Disease control OngoingThis study follows about 300 people with geographic atrophy, a late stage of age-related macular degeneration that causes vision loss, who are prescribed Syfovre (pegcetacoplan) by their doctor. Researchers will track side effects and how the drug is used in routine care over tim…
Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 17, 2026 11:39 UTC
-
New hope for PNH patients: Long-Term drug safety trial underway
Disease control OngoingThis study looks at the long-term safety and effectiveness of pegcetacoplan in people with PNH, a rare blood disorder. Participants must have completed a prior pegcetacoplan study and shown benefit. The main goal is to track side effects over time.
Phase: PHASE3 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 12, 2026 13:41 UTC
-
New hope for rare kidney patients: Long-Term drug trial underway
Disease control OngoingThis study looks at the long-term safety and effectiveness of a drug called pegcetacoplan for people with two rare kidney diseases: C3 glomerulopathy (C3G) and immune-complex membranoproliferative glomerulonephritis (IC-MPGN). About 100 adults who already completed a one-year stu…
Phase: PHASE3 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 11, 2026 20:48 UTC